Replies to post #250129 on Biotech Values

[Mufaso]

GPCR- Here are some selected comments from what Barrons had this to say at mid-day

New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.
https://www.barrons.com/articles/weight-loss-pills-structure-stock-b8da2d88

Shares of the obesity-focused biotech Structure Therapeutics plunged Monday morning, after the company reported new data on an experimental obesity pill that didn’t quite match up to earlier data of Eli Lilly’s experimental obesity pill.

While the safety results appeared strong, efficacy results seemed to fall short of market expectations.

In one trial, a Phase 2a study of the Structure drug, Type 2 diabetic patients in the high-dose groups saw a 1.02% placebo-adjusted reduction after 12 weeks in their HbA1c levels, a measure of their blood sugar, and a 3.3% placebo-adjusted reduction in weight.
While comparisons between trials are difficult, those efficacy results in diabetic patients after 12 weeks appear to be worse than those seen in Lilly’s trial of its experimental obesity pill orfoglipron, according to a note Monday morning from Leerink Partners analyst David Risinger. He wrote that after 12 weeks on Lilly’s orfoglipron, diabetic patients in a Phase 2 trial saw a reduction in HbA1c levels of 1.25% to 1.75%, and a weight loss of 5% to 6%.

In the Structure trial, obese patients who were not diabetic saw a 4.7% placebo-adjusted reduction in weight after eight weeks. Risinger wrote that those results were close to those seen in a Phase 2 trial of Lilly’s orfoglipron in non-diabetic obese patients, who had a 5% to 6% placebo-adjusted reduction in body weight after eight weeks.